# Pharmacological Countermeasures for High Altitude

> **NCT05300477** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **United States Army Research Institute of Environmental Medicine** · enrollment: 18 (estimated)

## Conditions studied

- Hypobaric Hypoxia

## Interventions

- **DRUG:** Acetazolamide
- **DRUG:** Erythropoietin

## Key facts

- **NCT ID:** NCT05300477
- **Lead sponsor:** United States Army Research Institute of Environmental Medicine
- **Sponsor class:** FED
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-05-27
- **Primary completion:** 2023-09-30
- **Final completion:** 2025-09-30
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-03-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05300477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05300477, "Pharmacological Countermeasures for High Altitude". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05300477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*